-

$undefined

N/A

(N/A)

Avadel Pharmaceuticals plc NASDAQ:AVDL Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.

Location: Block 10-1 Blanchardstown Corporate Park, Ballycoolin, Dublin, 15, Ireland | Website: www.avadel.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.283B

Cash

71.38M

Avg Qtr Burn

-28.54M

Short % of Float

13.18%

Insider Ownership

4.77%

Institutional Own.

79.51%

Qtr Updated

06/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
LUMRYZ (sodium oxybate) Details Excessive daytime sleepiness, Narcolepsy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LUMRYZ (sodium oxybate) Details Narcolepsy, Excessive daytime sleepiness, Cataplexy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LUMRYZ (sodium oxybate) Details Idiopathic hypersomnia	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.